Many adults stop GLP-1 therapy within a year with low restart rates, analysis finds
A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast 2023-2033
Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...
Crain's Chicago Business12h
Illinois AG urges FDA crackdown on 'counterfeit' GLP-1s
Kwame Raoul is among several state AGs raising the alarm following complaints about online teleheath company Hims & Hers ...
SHINE15h
China developed diabetes drug highlights biopharma surge
Between 2018 and 2024, China has launched 188 domestically developed innovative drugs – nearly double the number from the ...
Hosted on MSN14h
GLP-1RAs and opioid use disorder: a new frontier in addiction treatment
Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...